US FDA Approves AZ Antibody Treatment 'Evusheld' for Vaccine Side Effect Patients and Others

"Not an Alternative for the General Public Recommended for COVID-19 Vaccination"

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Yoo Je-hoon] The U.S. Food and Drug Administration (FDA) has authorized the use of AstraZeneca's antibody treatment 'Evusheld' to prevent COVID-19 infection in individuals with weakened immune systems or those who have experienced side effects from COVID-19 vaccines, major foreign media reported on the 8th (local time).

According to reports, the FDA approved the use of Evusheld for adults and adolescents who have not been infected with COVID-19 and have not recently been in contact with confirmed cases. Evusheld works by laboratory-produced antibodies remaining in the body for several months to suppress COVID-19 infection.

Clinical trials showed that Evusheld reduces the risk of COVID-19 infection by about 77%, and it is designed so that two doses provide protection for one year. AstraZeneca has agreed to supply 700,000 doses of Evusheld to the U.S. government.

However, the FDA emphasized that Evusheld is not a substitute for COVID-19 vaccination, which is recommended for the general public.

This content was produced with the assistance of AI translation services.